1. American College of Cardiology Presented by Dr. Adnan Kastrati
ISAR-DIABETES Trial
Sirolimus-eluting Stent compared with Paclitaxel-eluting Stent for Coronary Revascularization
Presented at
American College of Cardiology
Scientific Sessions 2005
Presented by Dr. Adnan Kastrati

2. Paclitaxel-eluting Stent
SIRTAX Trial
250 diabetic patients with symptomatic coronary artery disease, presence of at least one lesion covered with one or multiple stents of ≥50% stenosis, and anatomy suitable for coronary stenting
Randomized, single center
Sirolimus-eluting Stent
n=125
Paclitaxel-eluting Stent
n=125
Endpoints:
Primary- Late Loss (6 months)
Secondary- Angiographic restenosis (6 months) and TLR (9 Months)
Presented at ACC Scientific Sessions 2005

3. Angiographic Re-stenosis
ISAR-DIABETES Trial
Late Lumen Loss
Angiographic Re-stenosis
In-stent
p<0.002
In-lesion
P<0.001
p=0.03 mm
Sirolimus
Paclitaxel
Sirolimus
Paclitaxel
Sirolimus
Paclitaxel
Late lumen loss was lower in the sirolimus-eluting stent group compared with the paclitaxel-eluting stent group both in-stent and in-lesion.
Likewise, angiographic re-stenosis was also lower in the sirolimus-eluting stent group
Presented at ACC Scientific Sessions 2005

4. ISAR-DIABETES Trial
Primary Endpoint
(Late Loss)
Hazard Ratio [HR] 0.24
95% CI
p=0.002
The primary endpoint of late loss at 6 months was lower in the sirolimus-eluting stent group vs the paclitaxel-eluting stent.
The secondary endpoint of angiographic restenosis was also lower in the sirolimus-eluting stent group vs the paclitaxel-eluting stent.16.5% v. 6.9%; p=0.03
There was a trend towards reduced TLR in the siroliumus-eluting stent group. (12.2% vs. 6.4%; p=0.13)
(mm)
Presented at ACC Scientific Sessions 2005

5. ISAR-DIABETES Trial
Presented at ACC Scientific Sessions 2005

6. ISAR DIABETES Trial: Summary
Among patients with diabetes and coronary artery disease, treatment with the sirolimus-eluting stent was associated with less angiographic restenosis.
The findings of the ISAR DIABETES trial are consistent with the angiographic findings of the REALITY and SIRTAX trials, which demonstrated improvements in the angiographic parameters of late lumen loss with sirolimus-eluting stents.
Presented at ACC Scientific Sessions 2005